Optimizing NKT cell ligands as vaccine adjuvants

Leandro J. Carreño, Shalu Sharma, Steven A. Porcelli

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

NKT cells are a subpopulation of T lymphocytes with phenotypic properties of both T and NK cells and a wide range of immune effector properties. In particular, one subset of these cells, known as invariant NKT cells (iNKT cells), has attracted substantial attention because of their ability to be specifically activated by glycolipid antigens presented by a cell surface protein called CD1d. The development of synthetic α-galactosylceramides as a family of powerful glycolipid agonists for iNKT cells has led to approaches for augmenting a wide variety of immune responses, including those involved in vaccination against infections and cancers. Here, we review basic, preclinical and clinical observations supporting approaches to improving immune responses through the use of iNKT cell-activating glycolipids. Results from preclinical animal studies and preliminary clinical studies in humans identify many promising applications for this approach in the development of vaccines and novel immunotherapies.

Original languageEnglish (US)
Pages (from-to)309-320
Number of pages12
JournalImmunotherapy
Volume6
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Natural Killer T-Cells
Glycolipids
Vaccines
Ligands
Galactosylceramides
T-Lymphocytes
Natural Killer Cells
Immunotherapy
Membrane Proteins
Vaccination
Antigens
Infection
Neoplasms

Keywords

  • adjuvants
  • NKT cells
  • vaccine
  • α-galactosylceramide

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Optimizing NKT cell ligands as vaccine adjuvants. / Carreño, Leandro J.; Sharma, Shalu; Porcelli, Steven A.

In: Immunotherapy, Vol. 6, No. 3, 2014, p. 309-320.

Research output: Contribution to journalArticle

Carreño, Leandro J. ; Sharma, Shalu ; Porcelli, Steven A. / Optimizing NKT cell ligands as vaccine adjuvants. In: Immunotherapy. 2014 ; Vol. 6, No. 3. pp. 309-320.
@article{82ad03e518e740fbba4281fdf11f24f9,
title = "Optimizing NKT cell ligands as vaccine adjuvants",
abstract = "NKT cells are a subpopulation of T lymphocytes with phenotypic properties of both T and NK cells and a wide range of immune effector properties. In particular, one subset of these cells, known as invariant NKT cells (iNKT cells), has attracted substantial attention because of their ability to be specifically activated by glycolipid antigens presented by a cell surface protein called CD1d. The development of synthetic α-galactosylceramides as a family of powerful glycolipid agonists for iNKT cells has led to approaches for augmenting a wide variety of immune responses, including those involved in vaccination against infections and cancers. Here, we review basic, preclinical and clinical observations supporting approaches to improving immune responses through the use of iNKT cell-activating glycolipids. Results from preclinical animal studies and preliminary clinical studies in humans identify many promising applications for this approach in the development of vaccines and novel immunotherapies.",
keywords = "adjuvants, NKT cells, vaccine, α-galactosylceramide",
author = "Carre{\~n}o, {Leandro J.} and Shalu Sharma and Porcelli, {Steven A.}",
year = "2014",
doi = "10.2217/imt.13.175",
language = "English (US)",
volume = "6",
pages = "309--320",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Optimizing NKT cell ligands as vaccine adjuvants

AU - Carreño, Leandro J.

AU - Sharma, Shalu

AU - Porcelli, Steven A.

PY - 2014

Y1 - 2014

N2 - NKT cells are a subpopulation of T lymphocytes with phenotypic properties of both T and NK cells and a wide range of immune effector properties. In particular, one subset of these cells, known as invariant NKT cells (iNKT cells), has attracted substantial attention because of their ability to be specifically activated by glycolipid antigens presented by a cell surface protein called CD1d. The development of synthetic α-galactosylceramides as a family of powerful glycolipid agonists for iNKT cells has led to approaches for augmenting a wide variety of immune responses, including those involved in vaccination against infections and cancers. Here, we review basic, preclinical and clinical observations supporting approaches to improving immune responses through the use of iNKT cell-activating glycolipids. Results from preclinical animal studies and preliminary clinical studies in humans identify many promising applications for this approach in the development of vaccines and novel immunotherapies.

AB - NKT cells are a subpopulation of T lymphocytes with phenotypic properties of both T and NK cells and a wide range of immune effector properties. In particular, one subset of these cells, known as invariant NKT cells (iNKT cells), has attracted substantial attention because of their ability to be specifically activated by glycolipid antigens presented by a cell surface protein called CD1d. The development of synthetic α-galactosylceramides as a family of powerful glycolipid agonists for iNKT cells has led to approaches for augmenting a wide variety of immune responses, including those involved in vaccination against infections and cancers. Here, we review basic, preclinical and clinical observations supporting approaches to improving immune responses through the use of iNKT cell-activating glycolipids. Results from preclinical animal studies and preliminary clinical studies in humans identify many promising applications for this approach in the development of vaccines and novel immunotherapies.

KW - adjuvants

KW - NKT cells

KW - vaccine

KW - α-galactosylceramide

UR - http://www.scopus.com/inward/record.url?scp=84899553729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899553729&partnerID=8YFLogxK

U2 - 10.2217/imt.13.175

DO - 10.2217/imt.13.175

M3 - Article

C2 - 24762075

AN - SCOPUS:84899553729

VL - 6

SP - 309

EP - 320

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 3

ER -